Why this conversation matters

Insurance does not cover most compounded therapies. The patient is paying out of pocket, often for a multi-month protocol. The cost conversation, handled poorly, leaves patients feeling oversold. Handled well, it builds trust that compounds over the lifecycle of the relationship.

Lead with value, not price

The first cost conversation should be framed around what the patient is solving for, not the price tag.

"The protocol I am recommending runs about [X dollars] per month. It is a meaningful investment, and I want you to be clear on what you are getting for it: [specific clinical outcome they came in for], with ongoing clinician oversight and a 503A pharmacy that compounds to the dose you actually need."

The patient already knows it costs money. What they want to know is whether it is worth it.

Be honest about timelines

Patients sometimes assume effects within weeks. Most peptide protocols take 60 to 90 days to produce visible effects. GLP-1s often show appetite changes within a week but body composition changes over months.

Setting the timeline up front prevents the patient from feeling like the money is being wasted because nothing visible has happened by day 30.

"Most patients on this protocol start to feel changes around weeks 4 to 6 and see measurable effects by week 12. I will see you at week 4 to make sure you are on track."

Talk about what is not in scope

The clinician's job is to write prescriptions that fit. The clinician's job is not to convince a patient to spend money. If the therapy is borderline or the cost is meaningful for this patient's situation, say so.

"This protocol can help with what you are describing. It is also expensive enough that I want to be clear: if the lifestyle basics are not in place, the medication will not do the work alone. Are sleep and protein where they need to be? If not, that is a cheaper first step."

The patient who hears this once trusts you more for the next twelve months.

When to recommend a less-expensive starting point

Sometimes the right answer is "let us start with something less intensive." A patient interested in a multi-peptide stack might do better starting with one. A patient curious about GLP-1 might benefit more from a nutrition consult first.

You do not lose patients by recommending less. You lose them by recommending more than they needed.

On refills and ongoing protocols

Patients on long-running protocols (GLP-1s, ongoing NAD) appreciate having the renewal conversation framed proactively rather than every refill.

"We are 90 days into this. You are responding the way I would hope. I want to plan the next 6 months with you rather than rebook a consult every refill. Here is what I am thinking, and here is what it costs."

This shifts the dynamic from transactional to longitudinal.